B
Bull
Bull · 25%ADVM
$3.08
情境價格
$4.360
+0.102 (+2.35%)收盤時
Loading chart…
- High
- 4.379
- Open
- 4.240
- VWAP
- 4.32
- Vol
- 1.02M
- Mkt Cap
- 144.88M
- Low
- 4.230
- Amount
- 4.42M
- EV/EBITDA, TTM
- 0.05
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. It discovers and develops gene therapy product candidates that provide durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD). Its other partnered programs include BGTF-027 (AAV.7m8-L-opsin), a gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.
Analyst Ratings (3)
+12.39% upside
Buy
2 Buy
1 Hold
0 Sell
Current: 4.36
最低
4.00
平均
4.90
最高
5.50
H.C. Wainwright
Neutral
$5
2025-11-17
H.C. Wainwright
2025-11-17
目標價
$5
Neutral
RBC Capital
Sector Perform
$4
2025-10-28
RBC Capital
2025-10-28
目標價
$4
Sector Perform
Chardan
Neutral
$5
2025-10-24
Chardan
2025-10-24
目標價
$5
Neutral
Truist
Hold
$5
2025-10-24
Truist
2025-10-24
目標價
$5
Hold
RBC Capital
Sector Perform
$4
2025-05-15
RBC Capital
2025-05-15
目標價
$4
Sector Perform
估值指標
The current forward P/E ratio for Adverum Biotechnologies Inc (ADVM) is -0.46, compared to its 5-year average forward P/E of -1.72.
Alphio AI Price Scenarios for ADVM
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ADVM
事件時間軸
資訊
8.512-09PRnewswireEli Lilly Acquires Adverum at $3.56 per Share, Expanding Gene Therapy Potential
8.512-09SeekingAlphaEli Lilly finalizes purchase of Adverum Biotechnologies
8.512-01NewsfilterAdverum Biotechnologies to be Acquired by Eli Lilly for Up to $12.47 per Share
9.011-20NASDAQ.COMEli Lilly's Growing Drug Portfolio Boosts Sales Beyond GLP-1
7.011-19PRnewswireHalper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
ADVM FAQ — answered by Alphio AI
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. It discovers and develops gene therapy product candidates that provide durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD). Its other partnered programs include BGTF-027 (AAV.7m8-L-opsin), a gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
3 analysts cover ADVM: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 4.90.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。